Detecting tumor-specific DNA in blood is already common clinical practice in cancer patients with known mutational profiles (e.g. EGFR-mutant lung cancer) and therapy will be adapted according to presence or absence of certain tumor-specific mutations. The gene discussed is EGFR; the disease is neoplasm.